Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22287729 | 0.83 | HPGD (0.42) | ALDH1A1SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL22287817 | 0.81 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL22287638 | 0.81 | NPC1 (0.56) | ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL29939886 | 0.76 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL27168398 | 0.76 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL22287546 | 0.73 | BCL2A1 (0.42) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30800948 | 0.73 | TDP1 (0.42) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL29177547 | 0.73 | TDP1 (0.42) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL27168325 | 0.73 | TDP1 (0.42) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL29177535 | 0.70 | BCL2A1 (0.39) | ALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040770-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2023-02-09 | — | — | US | disclosed |
| US-20210276949-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| US-11028048-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-08 | — | — | US | disclosed |
| US-20200247747-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028048-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, MCHR2 | ALDH1A1 1710/4885SMN1; SMN2 1343/4885KMT2A 211/4885 |
| US-20210276949-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MCHR2 | ALDH1A1 1710/4885SMN1; SMN2 1343/4885KMT2A 211/4885 |
| US-20230040770-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MCHR2 | ALDH1A1 1710/4885SMN1; SMN2 1343/4885KMT2A 211/4885 |
| US-20200247747-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MCHR2 | ALDH1A1 1710/4885SMN1; SMN2 1343/4885KMT2A 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.